Recombinant Mouse Interleukin-1 receptor type 1 (Il1r1)

What is the basic structure of mouse IL1R1 and how does it differ from human IL1R1?

Mouse IL1R1 is an 80 kDa transmembrane protein that belongs to the immunoglobulin superfamily. The extracellular domain spans from Leu20 to Lys338 (amino acid sequence accession #P13504). The mouse IL1R1 shares approximately 63% amino acid sequence homology with human IL1R1 in their extracellular domains . The receptor contains multiple immunoglobulin-like domains in its extracellular portion that are critical for ligand binding. When produced as a recombinant protein, it is often fused with the Fc region of human IgG1 (Pro100-Lys330) to create a chimeric protein with enhanced stability and detection capabilities .

What cell types express IL1R1 in mouse models, and how can expression patterns be characterized?

IL1R1 is expressed predominantly by T cells, fibroblasts, and endothelial cells . In the central nervous system, both neurons and glial cells express the receptor. Specifically, the murine neuroblastoma cell line C1300 has been shown to express type I rather than type II IL-1 receptor mRNA . Expression patterns can be characterized through several methodologies:

• RT-PCR followed by Southern blotting to detect mRNA transcripts

• Flow cytometry using indirect immunofluorescence with rat anti-mouse type I IL-1 receptor monoclonal antibodies to detect protein expression on cell membranes

• Immunohistochemistry for tissue-specific expression patterns

Research has confirmed that mouse brain expresses both type I and type II IL-1 receptor mRNA and proteins, with evidence supporting the synthesis and expression of type I IL-1 receptors specifically by neurons .

How do IL1R1 and IL1R2 differ functionally, and why is this important for experimental design?

IL1R1 and IL1R2 are structurally related but functionally distinct receptors. IL1R1 is an 80 kDa transmembrane protein that mediates cellular responses to IL-1, while IL1R2 is a 68 kDa transmembrane protein that acts primarily as a decoy receptor. The two receptors share approximately 28% sequence identity in their extracellular domains but do not heterodimerize into a receptor complex .

When designing experiments, researchers must consider:

• IL1R2 is expressed on B lymphocytes, neutrophils, monocytes, large granular leukocytes, and endothelial cells

• IL1R1 is the signaling receptor that initiates biological responses

• IL1R2 can sequester IL-1 without signaling, potentially attenuating IL-1 responses

• Selective targeting of IL1R1 versus IL1R2 may be necessary for investigating specific IL-1-mediated pathways

This distinction is critical for interpreting results when targeting IL-1 signaling pathways in research models.

What are the optimal storage and handling conditions for recombinant mouse IL1R1 Fc chimera proteins?

For optimal performance and longevity of recombinant mouse IL1R1 Fc chimera proteins, researchers should follow these storage and handling guidelines:

• Receipt and Initial Storage: Upon receipt, immediately store the lyophilized protein at -20°C to -70°C .

• Reconstitution Method: Reconstitute at 100 μg/mL in sterile PBS. Gentle agitation during reconstitution is recommended to ensure complete dissolution .

• Post-reconstitution Storage:

  • Short-term storage (≤1 month): 2-8°C under sterile conditions

  • Long-term storage (≤3 months): -20°C to -70°C under sterile conditions

• Freeze-thaw Considerations: Use a manual defrost freezer and avoid repeated freeze-thaw cycles as these significantly reduce protein activity .

• Working Solution Preparation: When preparing working dilutions, use appropriate buffers containing carrier proteins (typically BSA) unless the application requires carrier-free conditions.

Following these guidelines will help maintain protein stability and biological activity throughout the experimental timeline.

How can researchers accurately assess the biological activity of recombinant mouse IL1R1?

The biological activity of recombinant mouse IL1R1 Fc chimera can be accurately assessed through functional inhibition assays, particularly by measuring its ability to neutralize IL-1α-dependent cellular responses. A standard method involves:

• Cell-based Bioassay: The inhibitory activity is typically measured using D10.G4.1 mouse helper T cells, which proliferate in response to IL-1α .

• Quantitative Assessment: Approximately 0.005-0.015 μg/mL of IL-1 sRI/Fc chimera will inhibit 50% of the biological response induced by 50 pg/mL of recombinant mouse IL-1α .

• Quality Control Parameters:

  • Purity assessment: >90% by SDS-PAGE under reducing conditions, visualized by silver stain

  • Molecular weight verification: 95-110 kDa under reducing conditions

  • Endotoxin level: <1.0 EU per 1μg of protein by the LAL method

• Alternative Assessment Methods:

  • Surface plasmon resonance to measure binding kinetics with IL-1 ligands

  • Co-immunoprecipitation to verify interaction with natural binding partners

  • Cell-based reporter assays measuring inhibition of IL-1-induced signaling pathways

These methodologies provide complementary approaches to verify both the binding capacity and functional activity of the recombinant protein.

What experimental considerations are important when using carrier-free versus BSA-containing recombinant IL1R1 preparations?

The choice between carrier-free (CF) and BSA-containing preparations of recombinant IL1R1 requires careful consideration based on experimental requirements:

Carrier-Free Preparations:

• Recommended for applications where BSA might interfere with the experimental outcome

• Essential for protein conjugation, immobilization, and certain imaging techniques

• Critical for mass spectrometry and proteomic analyses

• Required for in vivo applications where minimizing additional protein exposure is necessary

BSA-Containing Preparations:

• Preferred for cell or tissue culture applications and as ELISA standards

• Provide enhanced protein stability and increased shelf-life

• Allow storage at more dilute concentrations

• May stabilize the protein against surface adsorption and aggregation

Key Experimental Considerations:

• For receptor binding studies or protein-protein interaction assays, carrier-free preparations minimize non-specific interactions.

• For long-term storage or protocols requiring multiple freeze-thaw cycles, BSA-containing preparations offer greater stability.

• When designing blocking experiments where total protein concentration matters, account for the BSA contribution in BSA-containing preparations.

• For applications requiring precise protein quantification, carrier-free preparations eliminate the variability introduced by carrier proteins.

The formulation choice should be guided by the specific experimental requirements and downstream applications.

How does IL1R1 signaling contribute to tumor microenvironment modulation and cancer progression?

IL1R1 signaling plays a significant role in shaping the tumor microenvironment (TME) and promoting cancer progression through multiple mechanisms:

These findings highlight the potential therapeutic value of targeting IL1R1-expressing CAFs in colorectal cancer and potentially other solid tumors, suggesting that IL1R1 inhibition could modulate the TME toward an anti-tumor phenotype.

What role does IL1R1 play in the central nervous system, and how can it be studied in neurological models?

IL1R1 serves multiple functions in the central nervous system (CNS) and can be studied through various neurological models:

CNS Expression and Localization:

• Both type I and type II IL-1 receptor mRNA and proteins are expressed in the mouse brain

• Neurons specifically synthesize and express type I IL-1 receptors

• The neuroblastoma cell line C1300 predominantly expresses type I rather than type II IL-1 receptor mRNA

Functional Roles in Neurological Processes:

• Neuroinflammation: IL1R1 mediates inflammatory responses in the CNS, contributing to both protective and detrimental outcomes

• Neuroprotection: IL-1α administration has demonstrated neuroprotective and neuro-restorative effects following experimental ischemic stroke

• Neuronal Signaling: IL1R1 activation influences synaptic transmission and neuronal excitability

Methodological Approaches for CNS Studies:

• Expression Analysis:

  • RT-PCR followed by Southern blotting to detect receptor transcripts in brain tissue

  • Flow cytometry with anti-IL1R1 antibodies to identify receptor expression on neuronal cells

  • Immunohistochemistry for spatial distribution in brain regions

• Functional Assessment:

  • In vivo models of neurological diseases with IL1R1 manipulation

  • Ex vivo brain slice cultures to assess IL-1 responses

  • Primary neuronal cultures examining IL1R1-dependent signaling pathways

• Therapeutic Potential Investigation:

  • Administration of IL-1α in experimental stroke models demonstrates significant neuroprotective effects

  • IL1R1 antagonism studies to evaluate neuroinflammation modulation

Understanding IL1R1's role in the CNS provides insights into neuroinflammatory mechanisms and potential therapeutic approaches for neurological disorders.

How does IL1R1 genetic knockout or pharmacological inhibition affect experimental disease models?

IL1R1 genetic knockout or pharmacological inhibition demonstrates significant effects across various experimental disease models:

Cancer Models:

• Fibroblast-specific IL1R1 knockout reduces tumor growth in vivo

• IL-1 receptor antagonist (Anakinra) administration similarly decreases tumor growth

• These interventions lead to reduced intratumoral Th17 cell infiltration

• Blocking IL1R1 signaling in cancer-associated fibroblasts attenuates their pro-tumorigenic effects

Neurological Models:

• IL1R1 modulation affects outcomes in experimental stroke models

• IL-1α administration can be neuroprotective and neuro-restorative following ischemic stroke

• IL1R1 signaling influences neuroinflammation and neuronal survival

Immunological Models:

• IL1R1 inhibition affects T cell activation and expansion of CD11b+ Gr1+ cells in liver injury models

• IL1R1 signaling plays roles in antimicrobial immunity by regulating TNFR signaling and caspase-3 activation

• IL-1 family cytokines function as mucosal vaccine adjuvants for inducing protective immunity

Methodological Considerations for IL1R1 Inhibition Studies:

• Genetic Approaches:

  • Cell-specific conditional knockout models provide refined understanding of cell-specific IL1R1 functions

  • Global IL1R1 knockout may have compensatory mechanisms that confound interpretation

• Pharmacological Approaches:

  • Anakinra (recombinant IL-1Ra) provides competitive inhibition of IL-1 binding to IL1R1

  • Soluble IL1R1-Fc fusion proteins act as decoy receptors, with approximately 0.005-0.015 μg/mL inhibiting 50% of IL-1α biological response

  • Anti-IL1R1 antibodies offer alternative inhibition strategies

• Combinatorial Approaches:

  • Combining IL1R1 inhibition with other immunomodulatory strategies may reveal synergistic therapeutic effects

  • Temporal considerations of inhibition (prophylactic vs. therapeutic) yield different outcomes

These studies collectively highlight IL1R1 as a significant therapeutic target across multiple disease contexts, with particular promise in cancer, neurological disorders, and inflammatory conditions.

What are the optimal approaches for detecting and quantifying IL1R1 expression in various experimental systems?

Researchers can employ several complementary techniques to detect and quantify IL1R1 expression across experimental systems:

Nucleic Acid-Based Detection:

• RT-PCR with Southern Blotting:

  • This combined approach has successfully identified both type I and type II IL-1 receptor transcripts in mouse brain tissue

  • Use oligonucleotide probes specific to IL1R1 sequences for high specificity

  • Quantitative RT-PCR provides relative quantification of expression levels

• RNA-Seq/Single-Cell RNA-Seq:

  • Enables comprehensive transcriptomic profiling of IL1R1 alongside other genes

  • Single-cell approaches reveal cellular heterogeneity in IL1R1 expression

  • Particularly valuable for identifying IL1R1+ subpopulations, as demonstrated in studies of cancer-associated fibroblasts

Protein-Based Detection:

• Flow Cytometry:

  • Successfully used to identify IL1R1 protein on cell membranes using indirect immunofluorescence

  • Employs rat anti-mouse type I IL-1 receptor monoclonal antibodies

  • Provides quantitative assessment of receptor surface expression

• Western Blotting:

  • Detects IL1R1 protein in cell or tissue lysates

  • Confirms protein molecular weight (80 kDa for native IL1R1)

  • Can assess post-translational modifications affecting receptor function

• Immunohistochemistry/Immunofluorescence:

  • Reveals spatial distribution of IL1R1 in tissues

  • Enables co-localization studies with other markers

  • Particularly valuable for complex tissues like brain sections

Functional Detection:

• Receptor Binding Assays:

  • Using labeled recombinant IL-1 ligands to quantify binding capacity

  • Competitive binding assays to determine receptor affinities

  • Scatchard analysis for receptor density calculation

• Reporter Systems:

  • Cells expressing IL1R1-dependent reporter constructs

  • Measurement of downstream signaling events (NF-κB activation, MAPK phosphorylation)

  • Provides functional quantification of receptor activity

The selection of detection methods should be guided by the specific research question, experimental system, and available resources.

What are the best experimental designs for studying IL1R1-mediated signaling pathways?

To effectively study IL1R1-mediated signaling pathways, researchers should consider the following experimental designs:

Cell-Based Systems:

• Reporter Cell Lines:

  • Engineer cells with IL1R1 expression and pathway-specific reporters (e.g., NF-κB luciferase)

  • Monitor real-time activation of signaling events following IL-1 stimulation

  • Compare wild-type receptors with mutant variants to identify critical signaling domains

• Primary Cell Cultures:

  • Isolate primary cells from relevant tissues (e.g., neurons, fibroblasts, immune cells)

  • Compare responses in cells from wild-type vs. IL1R1 knockout animals

  • Use pharmacological inhibitors to dissect downstream signaling components

• Co-culture Systems:

  • Study cellular crosstalk mediated by IL1R1 signaling

  • Three-dimensional co-culture assays with cancer cells and IL1R1+ fibroblasts demonstrate enhanced cancer cell growth

  • Model cell-cell communication in complex tissue environments

Biochemical Approaches:

• Signal Transduction Analysis:

  • Western blotting for phosphorylated signaling intermediates (IRAK, TRAF6, MAPKs)

  • Immunoprecipitation to detect IL1R1 interaction with MyD88 and IL-1RAcP

  • Temporal analysis of signaling cascade activation

• Protein-Protein Interactions:

  • Co-immunoprecipitation of IL1R1 with adaptor proteins

  • Proximity ligation assays to visualize protein interactions in situ

  • FRET/BRET analyses for real-time interaction dynamics

Genetic Manipulation Strategies:

• Knockout/Knockdown Approaches:

  • Cell-specific conditional IL1R1 knockout models (e.g., fibroblast-specific knockout reduces tumor growth)

  • siRNA/shRNA knockdown for acute depletion studies

  • CRISPR/Cas9 editing to introduce specific receptor mutations

• Overexpression Systems:

  • Inducible expression systems to control timing and level of IL1R1 expression

  • Structure-function analysis using truncation or point mutants

  • Chimeric receptors to identify domain-specific functions

Pharmacological Interventions:

• Receptor Antagonism:

  • IL-1Ra (Anakinra) for competitive inhibition of IL-1 binding

  • Recombinant IL-1 sRI/Fc chimera inhibits IL-1α-dependent responses at 0.005-0.015 μg/mL

  • Blocking antibodies against specific receptor epitopes

• Pathway Inhibition:

  • Small molecule inhibitors targeting downstream components (IRAK1/4, TAK1, IKK)

  • Analysis of pathway cross-talk and redundancy

These experimental designs provide complementary approaches to dissect the complexity of IL1R1-mediated signaling in various biological contexts.

How can researchers optimize the production and purification of recombinant IL1R1 for functional studies?

Optimizing the production and purification of recombinant IL1R1 involves several critical considerations to ensure high yield, purity, and functional activity:

Expression System Selection:

• Mammalian Expression:

  • Preferred for IL1R1 Fc chimera proteins to ensure proper folding and post-translational modifications

  • Murine myeloma cell lines have been successfully used for recombinant mouse IL1R1 production

  • HEK293 or CHO cells provide alternative mammalian systems with high expression efficiency

• Bacterial Expression:

  • Suitable for protein fragments or domains without complex modifications

  • Requires optimization of solubility and refolding protocols

  • Often yields higher protein quantities but may compromise functional activity

Construct Design Optimization:

• Fusion Partners:

  • Fc fusion (human IgG1 Pro100-Lys330) enhances stability and facilitates purification

  • His-tag or GST-tag alternatives for applications where Fc is undesirable

  • Inclusion of precision protease cleavage sites if tag removal is required

• Domain Boundaries:

  • For mouse IL1R1, the extracellular domain spanning Leu20-Lys338 maintains optimal ligand binding

  • Codon optimization for the expression system

  • Signal sequence optimization for secretion efficiency

Purification Strategy:

• Affinity Chromatography:

  • Protein A/G chromatography for Fc-tagged constructs

  • Immobilized metal affinity chromatography (IMAC) for His-tagged proteins

  • Ligand affinity columns using immobilized IL-1

• Polishing Steps:

  • Size exclusion chromatography to remove aggregates

  • Ion exchange chromatography for charge variant separation

  • Endotoxin removal for in vivo applications (<1.0 EU per 1μg)

Quality Control Assessment:

• Purity Analysis:

  • SDS-PAGE under reducing conditions (>90% purity verified by silver stain)

  • Mass spectrometry for accurate molecular mass determination

• Functional Verification:

  • Bioactivity testing through inhibition of IL-1α-dependent proliferation in D10.G4.1 mouse helper T cells

  • Verification that 0.005-0.015 μg/mL inhibits 50% of the response to 50 pg/mL rmIL-1α

  • Binding kinetics analysis via surface plasmon resonance

Formulation Considerations:

• Buffer Optimization:

  • Typically formulated as a lyophilized product from a 0.2 μm filtered solution in PBS

  • Addition of stabilizers for liquid formulations

  • Carrier-free preparations for applications where BSA may interfere

• Storage Recommendations:

  • Lyophilized storage at -20 to -70°C

  • Reconstitution at 100 μg/mL in sterile PBS

  • Avoidance of repeated freeze-thaw cycles

Following these optimized approaches ensures the production of high-quality recombinant IL1R1 suitable for diverse functional studies.

How does the microenvironment affect IL1R1 expression and signaling in different tissue contexts?

The microenvironment significantly influences IL1R1 expression and signaling in a tissue-specific manner, with complex regulatory mechanisms:

Cancer Microenvironment:

• Fibroblast Heterogeneity:

  • IL1R1+ cancer-associated fibroblasts (CAFs) represent a distinct pro-tumorigenic subpopulation

  • The tumor microenvironment (TME) shapes fibroblast phenotypes, including IL1R1 expression patterns

  • Hypoxia, acidity, and ECM composition within the TME modulate IL1R1 signaling thresholds

• Immune Cell Interactions:

  • IL1R1+ CAFs influence T cell and macrophage functions, promoting immunosuppression

  • Th17 cell infiltration is regulated by IL1R1 signaling in the tumor context

  • Bidirectional communication between IL1R1-expressing cells and immune cells shapes the inflammatory milieu

Neurological Microenvironment:

• Cell Type-Specific Expression:

  • Neurons specifically synthesize and express type I IL-1 receptors in the brain

  • Glial cells differentially express IL1R1 depending on activation state

  • The blood-brain barrier influences IL-1 access to IL1R1-expressing cells

• Neuroprotective vs. Neurotoxic Signaling:

  • IL-1α administration demonstrates context-dependent neuroprotective effects in ischemic stroke models

  • Chronic vs. acute IL1R1 activation yields different outcomes in CNS tissues

  • The balance between pro- and anti-inflammatory factors in the neural microenvironment determines IL1R1 signaling consequences

Methodological Approaches to Study Microenvironmental Effects:

• Advanced Tissue Culture Models:

  • Three-dimensional co-culture systems recapitulating tissue architecture

  • Microfluidic devices with controlled cytokine gradients

  • Organoid models expressing IL1R1 in physiologically relevant patterns

• In Vivo Imaging Techniques:

  • Intravital microscopy to visualize IL1R1 activation in real-time

  • Reporter mice expressing fluorescent proteins under IL1R1-responsive promoters

  • FRET-based sensors to detect IL1R1 signaling activation in situ

• Single-Cell Analysis:

  • Single-cell RNA-seq to identify IL1R1+ cell subpopulations within complex tissues

  • Spatial transcriptomics to map IL1R1 expression with microenvironmental context

  • CyTOF analysis of signaling states in IL1R1+ cells from different microenvironments

Understanding these microenvironmental influences is crucial for developing targeted therapeutic strategies that modulate IL1R1 signaling in a context-appropriate manner.

What are the current challenges in IL1R1 research and potential approaches to address them?

Several significant challenges exist in IL1R1 research, with emerging approaches to address these limitations:

Challenge 1: Receptor Isoform Complexity

• Multiple IL1R1 splice variants exist with poorly characterized functions

• Difficulty in specifically targeting individual receptor isoforms

Potential Solutions:

• CRISPR/Cas9 approaches for isoform-specific tagging and knockout

• Development of isoform-selective antibodies and ligands

• Single-molecule imaging to track specific isoforms in living cells

Challenge 2: Redundancy in IL-1 Family Signaling

• Overlapping functions between IL-1 family members and their receptors

• Compensatory mechanisms when IL1R1 is inhibited

Potential Solutions:

• Combined targeting approaches addressing multiple IL-1 family receptors

• Temporal analysis of compensatory pathway activation following IL1R1 inhibition

• Systems biology approaches to model signaling network adaptations

Challenge 3: Context-Dependent Signaling Outcomes

• The same receptor activates different downstream pathways depending on cell type and environment

• Difficulty predicting intervention outcomes across diverse tissues

Potential Solutions:

• Cell type-specific conditional knockout models to delineate tissue-specific functions

• Proteomics analysis of IL1R1 signaling complexes in different cell types

• Development of biased ligands that selectively activate beneficial pathways

Challenge 4: Translation Between Mouse Models and Human Applications

• 37% sequence divergence between mouse and human IL1R1 extracellular domains

• Potential differences in signaling dynamics and regulatory mechanisms

Potential Solutions:

• Humanized mouse models expressing human IL1R1

• Comparative signaling studies between species

• Patient-derived xenograft models to study human IL1R1 in vivo

Challenge 5: Technical Limitations in Studying Membrane Receptor Dynamics

• Difficulties visualizing native IL1R1 at the cell surface

• Challenges in capturing transient signaling complexes

Potential Solutions:

• Advanced super-resolution microscopy techniques (STORM, PALM)

• Proximity labeling approaches (BioID, APEX) to identify the IL1R1 interactome

• Cryo-electron microscopy of IL1R1 signaling complexes

Challenge 6: Therapeutic Targeting Specificity

• Current IL-1 pathway inhibitors (like Anakinra) affect multiple IL-1 family members

• Balancing inhibition of pathological vs. protective IL1R1 signaling

Potential Solutions:

• Structure-based design of receptor-specific antagonists

• Cell type-targeted delivery of IL1R1 modulators

• Temporal control of inhibition using inducible systems or degraders

Addressing these challenges requires multidisciplinary approaches combining advanced molecular biology techniques, computational modeling, and innovative therapeutic strategies.

How might novel IL1R1-targeting approaches be developed for therapeutic applications?

The development of novel IL1R1-targeting therapeutic approaches represents an evolving frontier with multiple promising avenues:

Structure-Based Drug Design:

• Selective Antagonists:

  • Rational design of small molecules targeting specific IL1R1 epitopes

  • Peptide-based inhibitors derived from IL-1 binding regions

  • Allosteric modulators affecting receptor conformational states

• Biased Ligands:

  • Development of compounds that preferentially activate beneficial signaling pathways

  • Peptide derivatives that induce receptor internalization without activating inflammatory signaling

  • Engineered IL-1 variants with modified receptor interaction profiles

Advanced Biologics:

• Next-Generation Receptor Antagonists:

  • Engineered IL1R1 Fc fusion proteins with enhanced pharmacokinetics

  • Current IL-1 sRI/Fc chimeras inhibit IL-1α response at 0.005-0.015 μg/mL

  • Multivalent constructs to increase avidity and potency

• Combination Approaches:

  • Bispecific antibodies targeting IL1R1 and complementary inflammatory receptors

  • Co-delivery of IL1R1 antagonists with other immunomodulatory agents

  • Synergistic targeting of both ligand and receptor

Cell-Specific Targeting Strategies:

• Targeted Delivery Systems:

  • Nanoparticle-based delivery of IL1R1 modulators to specific cell populations

  • Cell type-selective antibody-drug conjugates

  • IL1R1 antagonists fused to cell-targeting domains

• Genetic Approaches:

  • AAV-mediated delivery of IL1R1 decoy receptors to specific tissues

  • CRISPR/Cas9-based modification of IL1R1 signaling components

  • mRNA therapeutics for transient modulation of IL1R1 expression

Potential Disease Applications:

• Cancer Immunotherapy:

  • Targeting IL1R1+ cancer-associated fibroblasts to reduce tumor growth and modulate the immune microenvironment

  • Combined checkpoint inhibitor and IL1R1 antagonist therapy

  • Reprogramming the tumor microenvironment by altering IL-1 signaling networks

• Neurological Disorders:

  • Precisely timed IL-1α administration for neuroprotection in stroke

  • Blood-brain barrier-penetrating IL1R1 modulators

  • Cell type-specific targeting within the CNS

• Inflammatory Conditions:

  • Tissue-selective IL1R1 antagonism to preserve beneficial immune functions

  • Temporal control of IL1R1 inhibition to match disease flares

  • Biomarker-guided patient selection for IL1R1-targeted therapies

Emerging Technologies Enabling These Approaches:

• Computational modeling of receptor-ligand interactions

• High-throughput screening of novel chemical libraries

• AI-driven drug design focused on IL1R1 binding pockets

• Advancements in protein engineering and stabilization

These innovative approaches could overcome limitations of current IL-1 pathway therapeutics by offering increased specificity, reduced side effects, and context-appropriate modulation of IL1R1 signaling.